XML 83 R68.htm IDEA: XBRL DOCUMENT v3.10.0.1
Acquisition Business Combination Details- Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Oct. 31, 2017
May 31, 2016
Dec. 31, 2017
Sep. 30, 2016
Jun. 30, 2016
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 06, 2017
Oct. 03, 2017
Business Acquisition [Line Items]                    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets                   $ 8,950,000,000
Business Combination, Consideration Transferred $ 11,155,000,000                  
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 75,000,000                  
Goodwill Acquired From Business Combination                   2,945,000,000
Research and development expenses           $ 5,018,000,000 $ 3,734,000,000 $ 5,098,000,000    
Goodwill, Period Increase (Decrease)           $ (42,000,000)        
Payments to Outstanding Common Stockholders [Member]                    
Business Acquisition [Line Items]                    
Payments to Acquire Businesses, Gross 10,420,000,000                  
Payments to Vested Equity Award Holders [Member]                    
Business Acquisition [Line Items]                    
Payments to Acquire Businesses, Gross 645,000,000                  
Payments to Warrant Holders [Member]                    
Business Acquisition [Line Items]                    
Payments to Acquire Businesses, Gross $ 15,000,000                  
Share Based Compensation Expense [Member]                    
Business Acquisition [Line Items]                    
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned                   $ 733,000,000
Kite Pharma, Inc [Member]                    
Business Acquisition [Line Items]                    
Business Acquisition, Share Price                   $ 180
Ownership Cell Design Labs, Inc.           12.20%        
Intangible Asset - axicabtagene ciloleucel (DLBCL) [Member]                    
Business Acquisition [Line Items]                    
Finite-Lived Intangible Assets, Period Increase (Decrease)     $ 6,200,000,000              
Finite-Lived Intangible Asset, Useful Life           18 years        
Intangible Asset - Daiichi Sankyo [Member]                    
Business Acquisition [Line Items]                    
Finite-lived Intangible Assets Acquired     91,000,000              
Finite-Lived Intangible Asset, Useful Life           14 years        
Cell Design Labs, Inc. [Member]                    
Business Acquisition [Line Items]                    
Business Combination, Consideration Transferred     150,000,000              
Regulatory Milestone-based Payments, Maximum     $ 322,000,000       322,000,000      
Carrying Value of Equity Interest Owned Prior to Acquisition                 $ 30,000,000  
Acquired IPR&D CDL             $ 172,000,000      
Nimbus Apollo, Inc. [Member]                    
Business Acquisition [Line Items]                    
Payments to Acquire Businesses, Gross   $ 400,000,000                
Research and development expenses       $ 200,000,000 $ 400,000,000          
Regulatory Milestone-based Payments, Maximum   $ 800,000,000